# Glucose and Lipid Metabolism on Antipsychotic Medication

> **NCT00515723** · NA · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 96 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Type 2 Diabetes Mellitus
- Hyperglycemia

## Interventions

- **DRUG:** risperidone
- **DRUG:** olanzapine
- **DRUG:** quetiapine
- **DRUG:** ziprasidone

## Key facts

- **NCT ID:** NCT00515723
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2019-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515723, "Glucose and Lipid Metabolism on Antipsychotic Medication". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00515723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*